Previous use of the ER pathway activity model in breast cancer patients produced functional ER signaling pathway activity scores with better predictive value regarding anti-estrogen therapy response than ER protein expression [13, 15, 16]. This evidence concerns the gene ESR1 and breast carcinoma.